Compound Database

Amyloid-beta 1-42 (Aβ42) is a 42-amino-acid peptide fragment that forms sticky plaques in the brains of people with Alzheimer's disease. It is produced when a larger protein called amyloid precursor protein (APP) is cut by specific enzymes. Researchers study it as both a disease marker and a potential therapeutic target.

Epithalon (also spelled Epitalon, chemical abbreviation AEDG) is a synthetic tetrapeptide composed of four amino acids — alanine, glutamic acid, aspartic acid, and glycine — originally derived from a natural peptide secreted by the pineal gland. It was developed by Russian researchers studying how the pineal gland influences biological aging. At 390.35 Da, it is one of the smallest peptides actively studied in longevity and cancer biology.

Delta Sleep-Inducing Peptide (DSIP) is a small neuropeptide of nine amino acids, first isolated from rabbit cerebrospinal fluid in 1974 by Swiss researchers studying sleep regulation. It is found naturally in the brain, pituitary gland, and gut, and has been studied for its potential role in sleep, stress response, and neuroendocrine regulation.

Oxytocin is a nine-amino-acid neuropeptide hormone produced in the hypothalamus and released by the pituitary gland. It plays a central role in social bonding, childbirth, breastfeeding, and a range of brain-based behaviors studied in both neuroscience and psychiatry.

Selank is a synthetic seven-amino-acid peptide developed in Russia as an analog of tuftsin, a naturally occurring immune-regulatory tetrapeptide. It was created by researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences and has been studied primarily for its anxiety-reducing and cognitive-enhancing properties.

Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH), consisting of the sequence Met-Glu-His-Phe-Pro-Gly-Pro and weighing 813.94 Da. It was developed in Russia as a nootropic and neuroprotective agent and has been approved for clinical use there since the 1990s.

Argireline, also sold under the trade name Acetyl Hexapeptide-3 (or Acetyl Hexapeptide-8 in updated INCI nomenclature), is a synthetic six-amino-acid peptide designed to reduce the appearance of facial wrinkles without injections. It was developed as a topical cosmetic alternative to botulinum toxin and is widely used in anti-aging skincare formulations.

Palmitoyl Pentapeptide-4, also sold under the trade name Matrixyl, is a synthetic cosmetic peptide made by attaching a fatty acid chain to a five-amino-acid sequence derived from collagen. It was designed to signal skin cells to produce more of their own structural proteins. You will find it in many anti-aging serums and creams.

Melanotan II is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH), developed in the 1980s at the University of Arizona. It was originally designed as a potential tanning agent but has since attracted research interest across several areas including sexual function, appetite regulation, and neurological conditions.

PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide developed from a naturally occurring hormone that regulates skin pigmentation. It acts on receptors in the brain rather than the vascular system, distinguishing it mechanistically from most other treatments for sexual dysfunction. Palatin Technologies developed PT-141 as a potential treatment for both male and female sexual disorders.

CJC-1295 DAC is a synthetic peptide analog of growth hormone-releasing hormone (GHRH), engineered to last far longer in the bloodstream than the natural hormone it mimics. The 'DAC' stands for Drug Affinity Complex, a chemical modification that allows the peptide to bind to albumin, a common blood protein, extending its half-life from minutes to approximately one week. It was developed to stimulate the pituitary gland to release more growth hormone over a sustained period.

Follistatin 344 is a 344-amino-acid isoform of the naturally occurring glycoprotein follistatin, a protein produced in the body that regulates muscle growth by binding to and blocking myostatin and activin. It is the most commonly studied synthetic form of follistatin in performance and muscle research. Researchers are investigating it primarily for its potential to increase skeletal muscle mass.

GHRP-2 (Growth Hormone Releasing Peptide-2), also known by its clinical name pralmorelin, is a synthetic six-amino-acid peptide that stimulates the body to release growth hormone. It was developed as a research tool to study the growth hormone axis and has been evaluated clinically as a diagnostic agent for growth hormone deficiency.

GHRP-6, or Growth Hormone Releasing Peptide-6, is a synthetic six-amino-acid peptide designed to stimulate the body's own release of growth hormone. It belongs to a class of compounds called GH secretagogues, meaning it prompts the pituitary gland to produce growth hormone rather than supplying it directly. Researchers study it for applications ranging from growth hormone deficiency diagnosis to organ protection.

Hexarelin, also known by its clinical name Examorelin, is a synthetic six-amino-acid peptide designed to stimulate the release of growth hormone from the pituitary gland. It belongs to a class of compounds called growth hormone secretagogues, meaning it triggers the body's own growth hormone production rather than supplying hormone directly. With a molecular weight of 887.04 Da, it is one of the more potent members of this peptide family studied to date.

IGF-1 DES, also known as Des(1-3)IGF-1, is a naturally occurring truncated form of insulin-like growth factor 1 (IGF-1) that is missing the first three amino acids at its N-terminal end. It is found in the brain and gut, and it is also produced synthetically for research purposes. With a molecular weight of 7371.4 Da, it is slightly smaller than full-length IGF-1 but behaves quite differently in the body.

IGF-1 LR3 (Long R3 IGF-1) is a synthetic, 83-amino-acid analog of human insulin-like growth factor 1, engineered to resist binding to IGF-binding proteins so that more of the active molecule reaches target tissues. It was developed as a research tool to study how IGF-1 drives cell growth, organ development, and metabolic regulation.

Ipamorelin is a synthetic five-amino-acid peptide (pentapeptide) that stimulates the pituitary gland to release growth hormone. It weighs 711.85 Da and carries the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. Researchers classify it as a growth hormone secretagogue, meaning it triggers the body's own growth hormone production rather than supplying hormone directly.

MK-677, also known as ibutamoren, is a non-peptide compound that stimulates the body to release more growth hormone by mimicking a natural hunger-signaling hormone called ghrelin. Unlike injected growth hormone, MK-677 is taken orally and works by activating the body's own hormone-producing system. It has been studied in clinical trials for conditions involving muscle loss, bone density, and growth hormone deficiency.

Mod GRF 1-29, also known as Modified GRF 1-29 or CJC-1295 without DAC, is a synthetic 29-amino-acid peptide designed to mimic the natural growth hormone-releasing hormone (GHRH) that the body produces in the hypothalamus. It was engineered with four specific amino acid substitutions to make it more stable and longer-lasting than the original GHRH fragment. Researchers study it as a tool for stimulating the pituitary gland to release growth hormone in a pulse-like, physiologically natural pattern.

Sermorelin is a synthetic peptide consisting of the first 29 amino acids of human growth hormone-releasing hormone (GHRH), the natural signal the brain uses to stimulate growth hormone production. It was developed as a diagnostic and therapeutic tool for conditions involving insufficient growth hormone secretion.

Tesamorelin, sold under the brand name Egrifta, is a synthetic 44-amino-acid peptide that mimics the body's natural growth hormone-releasing hormone (GHRH). It was developed specifically to address excess abdominal fat accumulation seen in people living with HIV who take antiretroviral therapy.

BPC-157, also called Body Protection Compound-157, is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a protein found naturally in human gastric juice. Researchers have studied it since the 1990s primarily for its effects on tissue repair and wound healing.

BPC-157 & TB-500 is a combined peptide blend pairing Body Protection Compound-157, a synthetic fragment of a human gastric protein, with Thymosin Beta-4, a naturally occurring actin-binding protein found in most human cells. Researchers study the blend because each peptide targets overlapping but distinct tissue-repair pathways, raising the hypothesis that combining them may produce additive recovery effects. Neither compound is approved for human use, and both are studied primarily in animal models.

GHK-Cu, also known as Copper Peptide or Glycyl-L-histidyl-L-lysine, is a naturally occurring tripeptide that binds copper ions and is found in human blood, saliva, and urine. It was first identified in human plasma in the 1970s and declines significantly with age. Researchers study it for its roles in skin repair, wound healing, anti-inflammatory activity, and tissue regeneration.

GLOW Peptide Blend is a proprietary combination of peptides marketed primarily in the recovery and aesthetic wellness space, targeting skin health, tissue repair, and systemic restoration. Because it is a blend rather than a single defined compound, its exact composition is not publicly disclosed, and no standardized molecular formula or sequence applies to the blend as a whole. It sits at the intersection of recovery science and cosmetic peptide research.

KLOW, also marketed as KLOW Blend, is a multi-peptide research blend combining several individual peptide compounds into a single formulation intended for recovery-focused research applications. It is not a single defined molecule but rather a proprietary combination whose precise components and ratios are not fully disclosed in peer-reviewed literature. Because of this, KLOW lacks an independent molecular formula, sequence, or CAS number.

KPV (Lys-Pro-Val) is a synthetic tripeptide derived from the last three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring hormone with anti-inflammatory properties. Weighing just 358.43 Da, it is one of the smallest biologically active peptide fragments studied in inflammation and gut health research.

TB-500 is a synthetic peptide fragment derived from thymosin beta-4, a naturally occurring protein found in nearly all human and animal cells. It consists of a 43-amino-acid sequence corresponding to the actin-binding region of the full thymosin beta-4 molecule, with a molecular weight of 4963.5 Da. Researchers study it primarily as a tissue repair and recovery agent.

AOD-9604, also known as Anti-Obesity Drug 9604, is a synthetic peptide derived from the fat-regulating region of human growth hormone (hGH). It consists of 16 amino acids corresponding to positions 177–191 of the hGH sequence, with a tyrosine residue added at the N-terminus. Researchers developed it to isolate the lipolytic properties of hGH without triggering the insulin-resistance or growth-promoting effects associated with the full hormone.

Retatrutide (also known as LY3437943) is an investigational peptide drug developed by Eli Lilly that activates three metabolic hormone receptors simultaneously. It is a 39-amino-acid synthetic peptide currently in clinical trials for obesity and type 2 diabetes. No approved version exists yet for public prescription use.

Semaglutide is a synthetic peptide drug that mimics a natural gut hormone called GLP-1, which the body releases after eating. It is sold under the brand names Ozempic (for type 2 diabetes) and Wegovy (for weight management). Weighing 4113.58 Da, it is designed to last a full week in the body, making once-weekly dosing possible.

Tirzepatide, sold under the brand names Mounjaro and Zepbound, is a synthetic peptide drug that targets two hormonal receptors in the body to regulate blood sugar and body weight. It was developed by Eli Lilly and is the first approved drug to simultaneously act on both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) systems. Tirzepatide weighs 4813.45 daltons and is administered as a once-weekly subcutaneous injection.

Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH), a naturally occurring decapeptide produced in the hypothalamus that controls the release of key reproductive hormones. It is a 10-amino-acid peptide with a molecular weight of 1182.31 Da, identical in sequence to endogenous human GnRH. Researchers and clinicians study it for its central role in regulating the hypothalamic-pituitary-gonadal (HPG) axis.

Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide naturally produced by the thymus gland that plays a central role in regulating the immune system. It was first isolated from thymic tissue in the 1970s and has since been studied for its ability to strengthen immune responses. A synthetic version, marketed as Thymalfasin, is approved for medical use in dozens of countries.

Anastrozole is a non-steroidal aromatase inhibitor approved for the treatment of hormone receptor-positive breast cancer in postmenopausal women. It works by blocking the enzyme that converts male hormones into estrogen, dramatically lowering estrogen levels in the body. It is sold under the brand name Arimidex and has been widely studied since the late 1990s.

Cabergoline is a long-acting dopamine agonist medication approved for treating elevated prolactin levels and Parkinson's disease. It works by mimicking dopamine in the brain, primarily acting on dopamine D2 receptors in the pituitary gland. It is sold under the brand name Dostinex, among others.

Clomiphene citrate, sold under the brand name Clomid, is a selective estrogen receptor modulator (SERM) that has been used clinically for decades to stimulate ovulation in women with fertility problems. It is a synthetic compound with a molecular weight of 598.1 Da that blocks estrogen receptors in specific tissues, tricking the body into producing more reproductive hormones. Researchers also study it in men as a non-surgical treatment for low testosterone.

Dutasteride, sold under the brand name Avodart, is a synthetic drug that blocks two enzymes responsible for converting testosterone into a more potent androgen called dihydrotestosterone (DHT). It is classified as a dual 5-alpha reductase inhibitor and has been studied primarily for hair loss and prostate conditions.

Enclomiphene citrate is the trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM) studied primarily for treating secondary hypogonadism in men. Unlike conventional testosterone replacement, it works by stimulating the body's own hormone production rather than supplying testosterone from an external source.

Exemestane (brand name Aromasin) is a steroidal aromatase inhibitor — a drug that permanently blocks the enzyme responsible for converting androgens into estrogen in the body. It is FDA-approved for treating certain types of breast cancer in postmenopausal women and, in combination with ovarian suppression, in premenopausal women. Unlike non-steroidal aromatase inhibitors, exemestane chemically binds to and inactivates its target enzyme.

Letrozole, sold under the brand name Femara, is a non-steroidal aromatase inhibitor that blocks the enzyme responsible for converting androgens into estrogen throughout the body. It was developed primarily for hormone-sensitive breast cancer and is now also used in fertility treatment.

Raloxifene (brand name Evista) is a selective estrogen receptor modulator (SERM) — a synthetic compound that mimics estrogen's beneficial effects in some tissues while blocking it in others. It was approved by the FDA in 1997 for preventing and treating osteoporosis in postmenopausal women. Researchers also study it for its effects on breast cancer risk reduction and cardiovascular markers.

Tamoxifen (brand name Nolvadex) is a synthetic selective estrogen receptor modulator (SERM) that has been used in clinical medicine since the 1970s. It blocks estrogen's effects in some tissues, such as breast, while acting like estrogen in others, such as bone and uterus. Researchers study it primarily in the context of hormone-receptor-positive breast cancer treatment and prevention.

Toremifene citrate, sold under the brand name Fareston, is a synthetic anti-estrogen drug belonging to the selective estrogen receptor modulator (SERM) class. It works by blocking estrogen receptors in certain tissues while activating them in others, producing tissue-specific hormonal effects.

Triptorelin (also sold as Decapeptyl and Trelstar) is a synthetic hormone analog that mimics gonadotropin-releasing hormone (GnRH), a natural signaling molecule produced in the brain. It is used medically to regulate sex hormone production, effectively reducing levels of testosterone or estrogen in the body. It is approved in multiple countries for treating prostate cancer, endometriosis, uterine fibroids, and central precocious puberty.

AICAR (also known as acadesine or AICA riboside) is a small synthetic molecule that mimics the effects of exercise at a cellular energy level. It activates a key metabolic enzyme called AMPK, which the body normally switches on during physical exertion or low energy states. Researchers study it as a tool to understand metabolic disease, heart protection, and nerve damage.

GW-501516, also known as Cardarine or GW1516, is a synthetic chemical compound that activates a protein called peroxisome proliferator-activated receptor delta (PPARδ), which regulates how cells burn fat and produce energy. Despite being grouped with SARMs in fitness communities, it is not a selective androgen receptor modulator — it is a PPARδ agonist with distinct biology. GlaxoSmithKline originally developed it to study metabolic disease and cardiovascular risk.